Twin Securities’s Aclaris Therapeutics ACRS Stock Holding History

Twin Securities’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-12,500	Closed	-$220K	–	20
2021 Q2	$220K	Buy	+12,500	New	+$284K	0.08%	14

Other funds holding ACRS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Twin Securities's ACRS Position: Q3 2021 in Review

Twin Securities sold out of Aclaris Therapeutics (ACRS) in Q3 2021, closing a stake of 12,500 shares — an estimated $220K sold.

Twin Securities first reported a position in ACRS in Q2 2021 and held it in 1 quarter. The position peaked at $220K in Q2 2021. 126 funds tracked by Wall St. Rank hold ACRS as of Q3 2021.

Twin Securities reported no remaining Aclaris Therapeutics position as of Q3 2021 after selling out during the quarter.
Twin Securities sold 12,500 Aclaris Therapeutics shares in Q3 2021, an estimated $220K.
Twin Securities first reported a position in Aclaris Therapeutics in Q2 2021 and held it in 1 quarter.
Twin Securities's Aclaris Therapeutics position peaked at $220K in Q2 2021.
126 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2021.

Based on Twin Securities's 13F filing for Q3 2021, filed 15 Nov 2021.